NPS Pharmaceuticals to Present at Barclays Capital Global Healthcare
Barclays Capital Global Healthcare Conference
BEDMINSTER, N.J. -- March 5, 2013
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the Barclays Capital
Global Healthcare Conference in Miami, Florida on Wednesday, March 13, 2013 at
11:15 a.m. ET. The presentation will be available as a live webcast with a
replay available approximately three hours after the presentation has
concluded. Interested parties may access the webcast from the investors’
calendar of events page on the NPS website at http://www.npsp.com/calendar.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering
therapies that transform the lives of patients with rare diseases worldwide.
The company’s lead product, Gattex® 0.05 mg/kg/d (teduglutide [rDNA origin])
for injection is FDA-approved for the treatment of adult patients with short
bowel syndrome (SBS) who are dependent on parenteral support. NPS is also
developing Natpara® (rhPTH[1-84]) for the treatment of adult
hypoparathyroidism and expects to submit its Biologic License Application
(BLA) to the FDA in 2013. NPS's earlier stage pipeline includes two calcilytic
compounds, NPSP790 and NPSP795, with potential application in rare disorders
involving increased calcium receptor activity, such as autosomal dominant
hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary
programs with a royalty-based portfolio of products and product candidates
that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals,
Kyowa Hakko Kirin, and Takeda GmbH.
NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335
Press spacebar to pause and continue. Press esc to stop.